2017 - Pharma Rep Focus

Merck settles with insurance companies over $1.4B claim tied to 2017 cyberattack: report

Fierce Pharma

JANUARY 4, 2024

billion claim after it was victimized by a crippling cyberattack in 2017. billion claim after it was victimized by a crippling cyberattack in 2017, Bloomberg Law reports. Merck has reportedly settled with insurance companies that contested the pharma giant’s $1.4

Insurance

Insurance Pharma

FDA Just Made Some Key Regulatory Changes to Make Cancer Cell Therapies More Accessible

MedCity News

JUNE 27, 2025

The FDA has eliminated a safety monitoring requirement and eased certain restrictions that had been in place since CAR T-therapies first reached the market in 2017. The agency and financial analysts say the changes should improve patient access to these personalized cancer treatments.

FDA

FDA Safety Marketing Patients

PTC wins FDA approval for first brain-delivered gene therapy Kebilidi

Fierce Pharma

NOVEMBER 14, 2024

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries, where it's branded as Upstaza.

FDA

With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer

Fierce Pharma

FEBRUARY 13, 2024

It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a combination dubbed Nalirifox to treat patients with newly diagnosed metastatic pancreatic cancer.

FDA

FDA Patients

CVS scheme diverted millions from underserved population, NY AG says

MedCity News

JULY 28, 2022

Attorney General Letitia James accused CVS of a scheme starting in 2017 to prevent New York safety net hospitals from using the company of their choice to obtain federal drug subsidies on prescriptions filled at CVS through the 340B program.

Prescription

Prescription Safety

Evernorth: 1 in 4 Adults Diagnosed with ADHD Don’t Get Treated

MedCity News

JUNE 28, 2023

in 2017. An Evernorth study found that in 2021, 25% of adults with ADHD did not receive any treatment, though this is a decrease from 38.5% About 21.4% of adults with ADHD received both medication and behavioral therapy in 2021, up from 12.9%

Medical

Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus

Fierce Pharma

SEPTEMBER 13, 2024

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus.

FDA

FDA Patients

Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension

Fierce Pharma

MARCH 20, 2024

After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.

FDA

Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case

Fierce Pharma

DECEMBER 6, 2023

In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. |

Medicine

'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study

Fierce Pharma

APRIL 8, 2024

Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.

FDA

FDA Medicine

Sanofi stands behind 'accuracy of our accounts' amid reports of French manipulation probe

Fierce Pharma

NOVEMBER 7, 2023

Since launching the Regeneron-partnered antibody Dupixent in 2017, Sanofi has relied on the star medicine for sales growth.

Medicine

Medicine Sales

Merck, insurers advance fight over cyberattack-related coverage to New Jersey Supreme Court

Fierce Pharma

JULY 27, 2023

scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. About a month and a half after Merck & Co. That didn't take long.

Insurance

W. Va. judge sides with drug distributors in bellwether opioid trial

MedCity News

JULY 7, 2022

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.

Biopharma

Biopharma Healthcare Healthcare

Report: More Traditional Medicare Enrollees Are Buying Medicare Supplement Coverage

MedCity News

APRIL 10, 2023

The share of traditional Medicare enrollees who bought Medicare Supplement coverage rose to 41% in 2021, compared to 35% in 2017, according to a report from America’s Health Insurance Plans. Medicare Supplement enrollees are three times less likely to have issues paying medical bills than those who only have traditional Medicare.

Insurance

Insurance Medical

Former Novartis execs cleared of Greek bribery charges after yearslong investigation

Fierce Pharma

MAY 31, 2023

After an investigation that dates back to 2017, four former Novartis executives and a Greek politician were cleared of bribery charges. After a yearslong investigation involving politicians and medical professionals alike, Novartis is looking to close the books on its Greek bribery imbroglio.

Doctors

Doctors Medical

Samsung Biologics upgrades another production pact, this time with Baxter for $223M

Fierce Pharma

JUNE 20, 2024

The revised deal, first established back in July of 2017, will now see Baxter pay Samsung upwards of $223 million for its manufacturing services through end of 2034. On a revised dealmaking spree this year, Korea’s Samsung Biologics is re-tooling its long-running drug manufacturing pact with Baxter Healthcare. |

Manufacturing

Manufacturing Healthcare Healthcare

Sanofi shakes up leadership as specialty care head Sibold departs to pursue outside opportunity

Fierce Pharma

AUGUST 31, 2023

Bill Sibold, who took over the company's specialty care unit in 2017 just after Dupixent's first approval, is leaving Sanofi effective immediately. For six years, Sanofi's specialty care chief Bill Sibold has helped the company make the most of its Regeneron-partnered immunology superstar Dupixent.

Lilly forks over $2.4M to settle federal agency's age discrimination lawsuit

Fierce Pharma

JUNE 27, 2023

Equal Employment Opportunity Commission, which sued the company in September over claims it had changed its hiring preferences in 2017 to prioritize recruitment of more millennials to its workforce. . | Eli Lilly will pay out $2.4 million as part of a settlement agreement with the U.S.

Recruitment

Takeda ends microbiome alliance with Finch Therapeutics after pipeline review

MedCity News

AUGUST 28, 2022

The biotech company had been collaborating with Takeda Pharmaceutical since 2017. The agreement termination means that two preclinical microbiome therapy candidates for inflammatory bowel disease will now return to Finch Therapeutics.

Pharmaceutical

Pharmaceutical Biopharma Pharma

Among Employers Offering Retiree Health Benefits, More Are Turning to MA Plans

MedCity News

DECEMBER 5, 2022

Of this group, 50% provide these benefits through a Medicare Advantage plan, up from 26% in 2017. Currently, only 13% of large employers — or companies with 200 or more employees — offer retiree health benefits, the Kaiser Family Foundation survey found.

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Media

Media Marketing Sales Pharma

Caris swells its planned IPO, seeking $5.7bn valuation

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Media

Media Marketing Sales Pharma

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Fierce Pharma

JULY 5, 2023

Since 2017, the company has sold off three PRVs—getting less in return for each successive sale. While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. | The price of priority review vouchers is falling.

FDA

FDA Sales

Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo

Fierce Pharma

AUGUST 22, 2023

Ingrezza was first approved in tardive dyskinesia in 2017. With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential. | The FDA approved Ingrezza capsules to treat adult with chorea associated with Huntington’s disease.

FDA

FDA Pharmaceutical

Apotex, Heritage and Breckenridge settle with purchasers in generics price-fixing case

Fierce Pharma

JANUARY 24, 2024

Apotex and two of its generics peers have agreed to settle with direct purchasers of their drugs in a price-fixing case that stretches all the way back to 2017. Over the years, myriad generic drugmakers have had to ante up fines and settlement fees for allegedly colluding on the prices of copycat drugs.

FDA approves Pfizer spinout SpringWorks' Ogsiveo as first treatment for disfiguring rare tumor type

Fierce Pharma

NOVEMBER 20, 2023

Patients with ultra-rare desmoid tumors now have an FDA-approved treatment, thanks to a drug made by SpringWorks Therapeutics, which spun out of Pfizer in 2017 with a portfolio of rare disease candidates. Thanks to a new FDA approval, patients with ultra-rare desmoid tumors now have an FDA-approved treatment.

FDA

FDA Patients

Biden proposes subsidizing drug middlemen for insulin

World of DTC Marketing

MARCH 31, 2022

Between 2017 and 2019, pharmacy benefit managers’ gross profit increased by 12 percent despite PBM retention of manufacturer rebates decreasing during this period, according to a report released on Dec. The report showed that the PBM gross profit increased from $25 billion to $28 billion between 2017 and 2019.

Insurance

Insurance Prescription Manufacturing Sales

New FDA head needs to examine the accelerated approval program

World of DTC Marketing

OCTOBER 21, 2021

The analysis focused on Medicare Part B and Part D spending — which covers outpatient medical care and prescription drugs, respectively, — in 2017, 2018 and 2019, the researchers said.

FDA

FDA Prescription Insurance Medicine

Most pharmas not ready for AI in customer engagement

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharma

Pharma Media Sales Marketing

Grail plans FDA filing for cancer blood test after new trial

pharmaphorum

JUNE 20, 2025

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

FDA

FDA Media Marketing Sales

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

pharmaphorum

JULY 1, 2025

billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio. billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio.

Media

Media Marketing Sales Pharma

Update: Rumour confirmed as Lilly buys Verve Therapeutics

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Media

Media Marketing Sales Pharma

Nektar eyes pivotal trials for eczema drug cast off by Lilly

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Media

Media Marketing Sales Pharma

AbbVie sucks

World of DTC Marketing

MARCH 10, 2022

The increase followed total Humira price hikes of 19 percent during 2017 and 2018. AbbVie, Humira’s manufacturer, kicked off 2020 with a price increase in excess of 7 percent on its mega-blockbuster brand-name treatment.

Prescription

Prescription Pharmaceutical products Pharmaceutical Marketing

Prediabetes numbers shocking

World of DTC Marketing

JUNE 27, 2022

According to a study published in the American Diabetes Association (ADA) journal Diabetes Care, the economic burden associated with diagnosed diabetes, undiagnosed diabetes and prediabetes, and gestational diabetes reached nearly $404 billion in 2017. Of that cost, $43.4 billion was associated with prediabetes.

Physicians

Physicians Pharma Insurance Doctors

ACIP backs block on flu vaccines with thimerosal additive

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Media

Media Marketing Sales Pharma

After rebuffing Biogen, Sage pairs off with Supernus

pharmaphorum

JUNE 16, 2025

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Sales

Sales Media Marketing Pharma

AbbVie Exploits Offshore Subsidiaries to Avoid Paying Taxes

World of DTC Marketing

JULY 8, 2022

In AbbVie’s’ own words, “The changes made by the 2017 tax law altered U.S. The investigation found that the Republican tax law has enabled AbbVie to generate the bulk of its sales and profits for brand-name drugs like Humira in the United States while booking those profits offshore for tax purposes.

Sales

Sales Prescription Pharma Manufacturing

Pharmaceutical training boost: how the growth and skills levy could shape industry development

European Pharmaceutical Review

FEBRUARY 17, 2025

Growth and Skills Levy – enabling greater training flexibility Since its introduction in 2017, the Apprenticeship Levy has generated over 21 billion from UK employers, increasing apprenticeship funding from 1.5 billion in 2017/18 to 2.5 billion in 2023/24.

Training

Training Pharmaceutical Government Manufacturing

A scientific approach to irrational consumer choices

World of DTC Marketing

DECEMBER 2, 2021

A review, authored by researchers at RTI International and the US Food and Drug Administration (FDA), looked at 38 studies published between 1982 and 2017 that examined outcomes reported by patients, prescribers, or both regarding their experience with DTC advertising in the US and New Zealand.

Food and Drug Administration

Food and Drug Administration Side effects FDA Prescription

Ukrainian research contributions to the UN Sustainable Development Goals

Clarivate

APRIL 14, 2022

Our research shows that Ukraine has contributed more than 5,000 scientific publications towards the UN Sustainable Development Goals since 2017, including on peace and justice initiatives (SDG-16). According to our data, Ukraine contributed a total of 5,863 scientific publications towards SDGs since 2017 (see figure 2).

Government

Government Education Distribution Food

Fierce Pharma Asia—BioNTech's ADC clinical hold; Takeda's leukemia bet; China NMPA's meeting with FDA

Fierce Pharma

JUNE 20, 2024

drug authorities met at the FDA's headquarters for the first time since 2017. Takeda has identified a potential challenger to Novartis' Scemblix. Senior officials from China and U.S. And more.

FDA

FDA Pharma

Study points to weaknesses in FDA accelerated approval path

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA

Preserving Patient Access to Compounded Medications Act of 2017

Pharmacy Times

SEPTEMBER 14, 2023

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

Medical

Medical Patients

Merck settles with insurance companies over $1.4B claim tied to 2017 cyberattack: report

FDA Just Made Some Key Regulatory Changes to Make Cancer Cell Therapies More Accessible

Trending Sources

PTC wins FDA approval for first brain-delivered gene therapy Kebilidi

With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer

CVS scheme diverted millions from underserved population, NY AG says

Evernorth: 1 in 4 Adults Diagnosed with ADHD Don’t Get Treated

Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus

Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension

Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case

'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study

Sanofi stands behind 'accuracy of our accounts' amid reports of French manipulation probe

Merck, insurers advance fight over cyberattack-related coverage to New Jersey Supreme Court

W. Va. judge sides with drug distributors in bellwether opioid trial

Report: More Traditional Medicare Enrollees Are Buying Medicare Supplement Coverage

Former Novartis execs cleared of Greek bribery charges after yearslong investigation

Samsung Biologics upgrades another production pact, this time with Baxter for $223M

Sanofi shakes up leadership as specialty care head Sibold departs to pursue outside opportunity

Lilly forks over $2.4M to settle federal agency's age discrimination lawsuit

Takeda ends microbiome alliance with Finch Therapeutics after pipeline review

Among Employers Offering Retiree Health Benefits, More Are Turning to MA Plans

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

Caris swells its planned IPO, seeking $5.7bn valuation

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo

Apotex, Heritage and Breckenridge settle with purchasers in generics price-fixing case

FDA approves Pfizer spinout SpringWorks' Ogsiveo as first treatment for disfiguring rare tumor type

Biden proposes subsidizing drug middlemen for insulin

New FDA head needs to examine the accelerated approval program

Most pharmas not ready for AI in customer engagement

Grail plans FDA filing for cancer blood test after new trial

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

Update: Rumour confirmed as Lilly buys Verve Therapeutics

Nektar eyes pivotal trials for eczema drug cast off by Lilly

AbbVie sucks

Prediabetes numbers shocking

ACIP backs block on flu vaccines with thimerosal additive

After rebuffing Biogen, Sage pairs off with Supernus

AbbVie Exploits Offshore Subsidiaries to Avoid Paying Taxes

Pharmaceutical training boost: how the growth and skills levy could shape industry development

A scientific approach to irrational consumer choices

Ukrainian research contributions to the UN Sustainable Development Goals

Fierce Pharma Asia—BioNTech's ADC clinical hold; Takeda's leukemia bet; China NMPA's meeting with FDA

Study points to weaknesses in FDA accelerated approval path

Preserving Patient Access to Compounded Medications Act of 2017

Stay Connected